240 results about "Growth inhibitory" patented technology

The antimicrobial activity of bovine bactericidal/permeability-increasing protein (bBPI)-derived synthetic peptides against mastitis-causing Gram-negative bacteria was evaluated. Three peptides were synthesized with sequences corresponding to amino acids 65-99 (bBPI_65-99), 142-169 (bBPI_142-169), or the combination of amino acids 90-99 and 148-161 (bBPI_{90-99,148-161}) of bBPI. The bBPI_{90-99,148-161} peptide demonstrated the widest spectrum of antimicrobial activity, with minimum inhibitory (MIC) and bactericidal (MBC) concentration values ranging from 16-64 μg/ml against Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp, and 64-128 μg/ml against Pseudomonas aeruginosa. None of the peptides exhibited any growth inhibitory effect on Serratia marcescens. The antimicrobial activity of bBPI_{90-99,148-161} was inhibited in milk, but preserved in serum. Finally, both bBPI_142-169 and bBPI_{90-99,148-161} were demonstrated to completely neutralize LPS. The peptide bBPI_{90-99,148-161} is a potent neutralizer of the highly pro-inflammatory molecule bacterial LPS and has antimicrobial activity against a variety of Gram-negative bacteria.

The administration of cytotoxic agents followed by the administration of heat shock protein 90 inhibitors, such as ansamycins, has a synergistic effect on the growth inhibition of cells. This synergy occurs at doses of each cytotoxic agent that normally only causes minimal growth inhibition of cells. Such combination therapy thus allows one to use lower doses of cytotoxic agents to avoid or reduce their respective toxicity to patients without compromising their growth inhibitory effects. Thus, these combinations can be used for the treatment of an animal, preferably a mammal, that has a cell proliferative disorder, whether the cells have wild-type Rb or are Rb deficient or Rb negative. One such method, directed to treating cell proliferative disorders includes the step of administering a therapeutic effective amount of a cytotoxic agent followed by administering a therapeutic effective amount of a heat shock protein 90 inhibitor. The cytotoxic agent may be a microtubule-affecting agent, topoisomerase II inhibitor, a platinum complex, paclitaxel, or a paclitaxel derivative. The HSP90 inhibitor may be an ansamycin, radicicol or a synthetic compound that binds to the ATP-binding site of HSP90.

The antifungal and cancer cell growth inhibitory activities of 1-(3′,4′,5′-trimethoxyphenyl)-2-nitro-ethylene (TMPN) were examined. TMPN was fungicidal for the majority of 132 reference strains and clinical isolates tested, including those resistant to fluconazole, ketoconazole, amphotericin B or flucytosine. Minimum fungicidal concentration/minimum inhibitory concentration (MFC/MIC) ratios were ≦2 for 96% of Cryptococcus neoformans clinical isolates and 71% of Candida albicans clinical isolates. TMPN was fungicidal for a variety of other basidiomycetes, endomycetes and hyphomycetes, and its activity was unaffected by alterations in media pH. TMPN was slightly cytotoxic for murine and human cancer cell lines (GI₅₀=1-4 μg/ml), and weakly inhibited mammalian tubulin polymerization (IC₅₀=0.60 μg/ml). TMPN may also be used as a biochemical probe for tubulin and fungal dimorphism studies.

The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba/F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.

The invention discloses a pro-drug as shown in general formula (I), which is formed by coupling camptothecin or a derivative of the camptothecin with non-linear configuration glycol polyethylene, wherein, the definition for varied groups is available in the specification. A physiological disposition research on nude mice discloses that: the pro-drug has a time-delay plasma concentration - time curve, and the plasma concentration can still be maintained at over 100ng/ml 72 hours after intravenous medication. Evaluation on physiological drug effect shows that the pro-drug has strong growth inhibiting effect against the LOVO HCT116 cell line transplantable tumor inoculated into the nude mice and also has obvious growth inhibitory activity against human lung carcinoma H460 cell line transportable tumor inoculated into the nude mice. The inhibition of the pro-drug is better than that of Irinotecan, a positive control drug and has no obvious systemic toxicity.

CD44, the receptor for hyaluronic acid, has complex functions in cellular physiology, cell migration and tumour metastasis. The inventors have previously found that human CD44 receptor overexpression in mouse fibrosarcoma cells inhibits subcutaneous tumour growth in mice [Kogerman et al., Oncogene 1997; 15:1407-16; Kogerman et al., Clin Exp Metastasis 1998; 16:83-93]. Here it is demonstrated that a tumour growth inhibitory effect of CD44 is caused by block of angiogenesis. Furthermore, the inventors have found that soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in cLick and mouse and thereby inhibits human tumour growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumours using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues is presented.

The invention provides the application of carbon nanotube-chitosan-phycocyanin complex in the preparation of antitumor drugs. The carbon nanotube-chitosan-phycocyanin complex is composed of multi-walled carbon nanotubes, Chitosan and spirulina phycocyanin are formed by non-covalent combination. The complex has good growth inhibitory effect on breast cancer MCF-7 cells and liver cancer HepG2 cells, especially under the irradiation of near-infrared light and visible light. The inhibitory effect was further strengthened, and all showed the characteristics of killing tumor cells. As an anti-tumor biomedical material, the carbon nanotube-chitosan-phycocyanin composite provided by the invention has broad prospects in photodynamic therapy and photothermal therapy of tumor cells.

The invention relates to Fenneropenaeus chinensis antibacterial protein and its coding gene, expression system, refolding system and application. The protein comprises amino acid sequences represented by SEQ ID No.2 in the sequence table or amino acid sequences represented by SEQ ID No.4 in the sequence table. The invention has the advantages that: a novel antibacterial protein Carcinin gene sequence is cloned from the Fenneropenaeus chinensis cDNA library, the Carcinin gene sequence encoding amino acid sequence is deduced; and the prokaryotic expressing system which is suitable for the recombinant expression in vitro of the antibacterial protein is screened out, thus the protein can be expressed efficiently, the recombinant protein can be refolded well, and the verification of biological functions of the recombinant protein shows that the recombinant protein has growth inhibitory effects on Grampositive bacteria and has no growth inhibitory effects on Gram negative bacteria. The clone and recombinant expression of the gene has an important application prospect in developing novel antibacterial drugs.

The object of the present invention is to provide a pharmaceutical composition for preventing or treating viral infectious diseases. The compounds of the present invention have extremely potent anti-HCV activity and HCV growth inhibitory effects, and since they also only demonstrate mild cytotoxicity in vivo, a pharmaceutical composition containing the compound of the present invention is extremely useful as an anti-HCV preventive/therapeutic agent.

The invention discloses a pure tin electroplating solution for inhibiting growth of tin whiskers and an application thereof. A mixed solution of methylsulphonic acid and sulfuric acid is adopted as an acidic plating solution, a mixed solution of alkyl sulfonic acid tin salt and hydrogen peroxide is adopted as tin salt, and antioxidants, adjuvants, brightening agents, wetting agents, surface-active agents and the like are added to the mixed solutions. In the application process, an unique electroplating solution preparing method and matters needing attention in use are adopted, and therefore the effect of inhibiting the growth of the tin whiskers is obvious compared with the application of a traditional electroplating solution; moreover, the growth speed of the tin whiskers is greatly reduced, and the growth of the tin whiskers on the surface of an electroplated part is reduced; moreover, plated layers electroplated through the method is good in flexibility and ductility, cracks of the plated layers can be well reduced, the ability to bear the temperature is flexible, and the practical value is high.

It is intended to provide a monoclonal antibody having a growth inhibitory activity against a cell having a human CD20 antigen which is produced by using, as immunogens, a human B cell line expressing the human CD20 antigen and a cell line originating in a non-human animal, which is different from an animal to be immunized and has been transformed with human CD20 DNA, and a monoclonal antibody obtained by chimerization or humanization of the above-described monoclonal antibody. These monoclonal antibodies show biological activities suitable for using as drugs.

This invention relates to a cytotoxic phenylallyl phenylacrylate as shown in formula (1) and its analogs or phenylpropyl phenylpropionate as shown in formula (2), its analogs and its offcinal salts or solvates. This invention also relates to the preparation method for these compounds and the intermediates for preparation. Besides, this invention still relates to the pharmacological use of these compounds and their blended composites. The compounds in this invention have growth inhibitory activity towards tumor cells and are estimated to be used as antineoplastics.

The invention discloses a functional targeting vector material distearoyl phosphatidylethanolamine-polyethylene glycol-polyethylenimine compound and a modified liposome thereof. According to the invention, a DSPE-PEG2000-PEI600 compound is taken as a targeting molecule to modify a drug-carrying liposome surface, so that the drug can selectively gather in tumor cells through a blood brain barrier effectively so as to generate a targeting effect. For instance, the drug uptake rate of C6 glioma cells and glioma stem cells is increased significantly, so that the drug can have strongest selective concentrated distribution on mitochondria of C6 glioma cells and glioma stem cells, shows stronger growth inhibitory effect on glioma cells, and shows stronger effects of crossing the blood brain barrier and killing glioma stem cells, i.e. dual targeting effect, and the cycle time of the drug in ICR mice and the gathering degree in tumor tissues can be prolonged, thus prolonging the life time of organisms.

The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.

The present invention discloses an antibody capable of binding to the PRG-3 protein and inhibiting the growth of cells expressing the PRG-3 protein. The growth inhibitory activity is cytotoxic activity, such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. The present invention also discloses a pharmaceutical composition, cell growth inhibitor, and an anticancer agent comprising the antibody of the present invention as an active ingredient. Examples of the type of cancer include hepatocellular carcinoma, lung cancer, colon cancer, and glioblastoma. In addition, the present invention discloses a method for diagnosing cancer by detecting expression of the PRG-3 protein or the gene encoding the PRG-3 protein, as well as a diagnostic agent and kit for use in the method.

The present invention relates to pharmaceutical composition containing a physiologically effective dose of a nanoparticle triterpene glycoside or nanoparticle triterpene complex, wherein said complex is a liposome encapsulated compound, or exosome-encapsulated compound.

The invention provides a pyrazolo-[1,5-a] pyrimidine derivative. The invention further provides activity screening results of the cell level and the target level of the compound and an anti-tumor application of the compound for treating diseases or symptoms, such as gastric cancer, lung cancer, cervical cancer, breast cancer or colon cancer. The invention further provides a relevant experiment for the cell level of the compound. The cell level comprises an inhibitory test on a TRPC6 channel and growth inhibitory activity on gastric cancer cells.

The invention provides a composition for reducing porphyrin in skin, and a preparation method and application thereof. The composition comprises a yeast/rice fermentation product filtrate, a yeast/zinc fermentation product, a bifida ferment lysate and a hamamelis virginiana extract. Through mutual cooperation and synergistic interaction of the yeast/rice fermentation product filtrate, the yeast/zinc fermentation product, the bifida ferment lysate and the hamamelis virginiana extract, the composition is improved in the effects of cleaning, oil control and barrier repair on facial skin, effectively inhibits grease secretion and adjusts the balance of skin micro-ecology; and meanwhile, the growth of pathogenic bacteria is inhibited, and grease secretion and excessive keratosis of hair follicle sebaceous gland ducts are inhibited, so porphyrin in the skin is effectively reduced.

The invention discloses a plant growth adjusting composition as well as a preparation and an application thereof. The plant growth adjusting composition is composed of following components in parts by weight: A: 1-9 parts of uniconazole and B: 1 part of mepiquat chloride. According to the plant growth adjusting composition, the mepiquat chloride and the uniconazole can be effectively mixed and the growth inhibition effect on plants can also be expressed.